Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering Agreement...

Sangamo BioSciences Announces Achievement of Key Milestone in Cell Engineering
Agreement With Genentech

RICHMOND, Calif., June 29 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc.
(Nasdaq: SGMO) today announced that a key research milestone has been achieved
in its Research and License Agreement with Genentech, Inc., a wholly-owned
member of the Roche Group, for the generation of cell lines with novel
characteristics for pharmaceutical protein production purposes using Sangamo's
proprietary zinc finger DNA-binding protein nuclease (ZFN) technology.
Genentech scientists demonstrated the successful knockout of two preselected
genes in a Chinese hamster ovary (CHO) cell line. The milestone achievement
triggered a payment from Genentech to Sangamo.

"Achievement of this milestone demonstrates the progress under our agreement
with Genentech," said Edward Lanphier, Sangamo's president and chief executive
officer. "Our ZFN technology is currently being used by major players in
pharmaceutical protein production to streamline the process of cell line
production, increase the yield and improve the characteristics of biologic
drugs, such as antibodies, that are manufactured in mammalian cells."

"Our ZFNs provide the gold standard technology for specifically editing target
genes in mammalian cells," stated Philip Gregory, D. Phil., Sangamo's vice
president of research. "Moreover, the efficiency of this approach obviates the
need for selection markers, thereby enabling the rapid generation of cell
lines in which multiple genes have been knocked out. Our proven ability to
quickly and selectively knock out multiple genes in the same cell line creates
endless possibilities for biopharmaceutical companies to improve their
manufacturing capability."

About Sangamo
Sangamo BioSciences, Inc. is focused on researching and developing zinc finger
DNA-binding protein (ZFP) technology for therapeutic gene regulation and
modification. By engineering ZFPs that recognize a specific DNA sequence
Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control
gene expression and, consequently, cell function. Sangamo is also developing
sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. The most
advanced ZFP Therapeutic(TM) development program is currently in Phase 2
clinical trials for evaluation of safety and clinical effect in patients with
diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to
evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of
HIV/AIDS. Other therapeutic development programs are focused on cancer,
neuropathic pain, nerve regeneration, Parkinson's disease and monogenic
diseases. Sangamo has established strategic partnerships with companies in
non-therapeutic applications of its ZFP Technology, including Dow
AgroSciences, Sigma-Aldrich Corporation Genentech and Pfizer. For more
information about Sangamo and the ZFP Technology, visit www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's
current expectations. These forward-looking statements include, without
limitation, references to the research and development of novel ZFP TFs and
ZFNs, strategic relationship with collaborators and achievement of research
milestones, and research applications of Sangamo's ZFP technology platform.
Actual results may differ materially from these forward-looking statements due
to a number of factors, including technological challenges, the ability of
Sangamo and its collaborators to develop commercially viable products and
technological developments by our competitors. See the company's SEC filings,
and in particular, the risk factors described in the company's Annual Report
on Form 10-K and its most recent Quarterly Report on Form 10-Q. Sangamo
assumes no obligation to update the forward-looking information contained in
this press release.

SOURCE Sangamo BioSciences, Inc.

Elizabeth Wolffe, Ph.D., of Sangamo BioSciences, Inc., +1-510-970-6000, Ext.
271, ewolffe@sangamo.com